Welcome to our dedicated page for ACMSY news (Ticker: ACMSY), a resource for investors and traders seeking the latest updates and insights on ACMSY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACMSY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACMSY's position in the market.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, purchased an additional 9,447 shares, raising his total holdings to 3,801,226 shares. Cerrone expressed confidence in the company's direction, aligning his interests with fellow shareholders. AccuStem is focused on enhancing cancer patient outcomes, aiming to provide essential tools and answers in oncology while fostering healthcare innovation.
AccuStem Sciences has announced its uplisting from the OTC Pink Sheets to the OTCQB, effective April 14, 2022, under the ticker "ACUT." This change aims to enhance visibility for retail and institutional investors and improve trading liquidity. The OTCQB is recognized by the SEC and requires companies to meet ongoing listing standards. CEO Wendy Blosser noted that this uplisting is crucial for expanding the shareholder base and raising capital for innovative cancer treatment products.
AccuStem Sciences announced a Common Stock Purchase Agreement with Tiziana Life Sciences, resulting in Tiziana purchasing 1,337,970 shares at $2.00 each, generating gross proceeds of $2,675,940. This transaction follows the Supplemental Demerger Agreement from October 5, 2021. The shares were not registered under the Securities Act of 1933, thus limiting their sale in the U.S. The company remains focused on enhancing cancer patient outcomes and highlights the inherent risks in forward-looking statements regarding its business strategies and financial health.
AccuStem Sciences, Inc. (OTC Pink: ACUT) announced that its common shares are now DTC eligible for electronic clearing and settlement in the U.S., enhancing trading efficiency and liquidity. This milestone is aimed at increasing awareness and expanding the shareholder base, moving the company closer to a NASDAQ listing. On March 23, 2022, shareholders of old AccuStem ADSs will convert to U.S. shares at a rate of 1:10. The company emphasizes its dedication to improving cancer patient outcomes while highlighting potential risks in its forward-looking statements.
AccuStem Sciences plans to uplist to the Nasdaq Capital Market following the formation of a new executive leadership team, including Wendy Blosser as CEO. With extensive experience in oncology, Blosser aims to enhance product commercialization. Alongside her, Jeff Fensterer and Joe Flanagan join as COO and CBO respectively to leverage their backgrounds in strategic growth. The company is also moving its headquarters to Phoenix, Arizona. This leadership assembly is seen as a pivotal step in developing AccuStem's clinical research and business strategies.
AccuStem Sciences, Inc. (OTC PINK: ACMSY) announced a significant breakthrough with the publication of new data in the European Journal of Cancer. The study revealed that StemPrintER effectively predicts the risk of distant recurrence in women with breast cancer. Analyzing 776 tumor samples, results showed that patients with a StemPrintER Risk Score Low had a mere 5.8% risk of distant recurrence at 10 years, compared to 23.2% for those with a High score. The findings highlight StemPrintER's potential in enhancing clinical decision-making and patient outcomes.
